Security
Lineage Cell Therapeutics, Inc. · LCTX
LCTXNYSE_AMERICANCommon stockCurrentCIK 876343Updated Oct 6, 2026
Name history
BIOTIME INC · through Aug 8, 2019
LCTX price & chart
Loading TradingView…
AMEX:LCTX on TradingView ↗About the company
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions. Lineage’s programs are based on its proprietary cell-based technology platform, AlloSCOPE™ (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and associated development and manufacturing capabilities. From this proprietary AlloSCOPE platform, Lineage develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or substantially identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages, and in some instances may be designed to have additional beneficial properties. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to
In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G - filed by BlackRock, Inc. regarding Lineage Cell Therapeutics, Inc.
4 filing
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 89,639,000Source | 96,594,000Source | 106,220,000Source | 90,799,000Source | 102,802,000Source | 109,533,000Source | 111,753,000Source | 108,483,000Source | 112,584,000Source | 113,218,000Source | 101,019,000Source | 123,664,000Source |
| Property, Plant and Equipment, NetUSD | 2,157,000Source | 2,013,000Source | 2,517,000Source | 2,255,000Source | 2,018,000Source | 2,497,000Source | 2,149,000Source | 2,104,000Source | 2,566,000Source | 2,251,000Source | 4,767,000Source | 5,673,000Source |
| GoodwillUSD | 10,672,000Source | 10,672,000Source | 10,672,000Source | 10,672,000Source | 10,672,000Source | 10,672,000Source | 10,672,000Source | 10,672,000Source | 10,672,000Source | 10,672,000Source | 10,672,000Source | 10,672,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 31,700,000Source | 46,540,000Source | 31,700,000Source | 31,700,000Source | 46,540,000Source | 31,700,000Source | 46,540,000Source | 46,540,000Source | 31,700,000Source | 46,540,000Source | 46,562,000Source | 46,692,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 40,463,000Source | 27,750,000Source | 37,355,000Source | 42,271,000Source | 29,622,000Source | 35,939,000Source | 47,886,000Source | 43,576,000Source | 40,791,000Source | 45,789,000Source | 35,442,000Source | 11,355,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 127,000Source | 405,000Source | 790,000Source | 256,000Source | 235,000Source | 806,000Source | 213,000Source | 77,000Source | 891,000Source | 638,000Source | 745,000Source | 297,000Source |
| Assets, CurrentUSD | 42,260,000Source | 34,401,000Source | 52,970,000Source | 43,844,000Source | 40,390,000Source | 56,164,000Source | 49,984,000Source | 45,716,000Source | 59,157,000Source | 50,997,000Source | 38,441,000Source | 60,000,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,647,000Source | 1,285,000Source | 1,351,000Source | 1,300,000Source | 1,659,000Source | 1,977,000Source | 1,866,000Source | 2,018,000Source | 2,485,000Source | 2,554,000Source | 2,204,000Source | 1,828,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,311,000Source | 2,362,000Source | 1,964,000Source | 1,817,000Source | 2,584,000Source | 2,127,000Source | 1,904,000Source | 2,855,000Source | 2,131,000Source | 2,144,000Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 68,843,000Source | 31,800,000Source | 46,422,000Source | 43,687,000Source | 35,927,000Source | 56,838,000Source | 34,098,000Source | 37,493,000Source | 69,238,000Source | 36,206,000Source | 38,996,000Source | 51,728,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 494,175,000Source | 469,268,000Source | 535,717,000Source | 490,551,000Source | 467,928,000Source | 529,656,000Source | 489,313,000Source | 466,571,000Source | 515,467,000Source | 484,722,000Source | 451,343,000Source | 440,280,000Source |
| Retained Earnings (Accumulated Deficit)USD | -467,849,000Source | -400,192,000Source | -470,328,000Source | -438,068,000Source | -397,158,000Source | -471,810,000Source | -407,604,000Source | -391,398,000Source | -466,998,000Source | -403,465,000Source | -384,856,000Source | -363,370,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -4,286,000Source | -2,890,000Source | -4,473,000Source | -4,098,000Source | -2,470,000Source | -3,971,000Source | -2,681,000Source | -2,771,000Source | -3,920,000Source | -2,876,000Source | -3,068,000Source | -3,571,000Source |
| Stockholders' Equity Attributable to ParentUSD | 22,040,000Source | 66,186,000Source | 60,916,000Source | 48,385,000Source | 68,300,000Source | 53,875,000Source | 79,028,000Source | 72,402,000Source | 44,549,000Source | 78,381,000Source | 63,419,000Source | 73,339,000Source |
| Liabilities and EquityUSD | 89,639,000Source | 96,594,000Source | 106,220,000Source | 90,799,000Source | 102,802,000Source | 109,533,000Source | 111,753,000Source | 108,483,000Source | 112,584,000Source | 113,218,000Source | 101,019,000Source | 123,664,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 9,382,000Source | 13,864,000Source | 8,016,000Source | 10,756,000Source | 15,275,000Source | 8,148,000Source | 13,089,000Source | 16,890,000Source | 11,367,000Source | 13,977,000Source | 17,960,000Source | 18,981,000Source |
| Operating Lease, Liability, CurrentUSD | 1,023,000Source | 1,083,000Source | 918,000Source | 998,000Source | 1,069,000Source | 833,000Source | 1,124,000Source | 1,052,000Source | 816,000Source | 1,097,000Source | 830,000Source | 916,000Source |
| Accounts Payable, CurrentUSD | 1,520,000Source | 1,599,000Source | 1,536,000Source | 1,497,000Source | 2,388,000Source | 1,591,000Source | 1,995,000Source | 2,211,000Source | 2,341,000Source | 1,174,000Source | 2,050,000Source | 2,393,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,515,000Source | 1,533,000Source | 1,333,000Source | 1,058,000Source | 1,768,000Source | 1,507,000Source | 1,013,000Source | 2,074,000Source | 1,534,000Source | 1,295,000Source | 1,979,000Source | 2,860,000Source |
| Deferred Income Tax Liabilities, NetUSD | 273,000Source | 273,000Source | 22,000Source | 273,000Source | 273,000Source | 22,000Source | 273,000Source | 273,000Source | 22,000Source | 273,000Source | 273,000Source | 2,076,000Source |
| Other Liabilities, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 2,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -1,244,000Source | -1,392,000Source | -1,118,000Source | -1,273,000Source | -1,425,000Source | -1,180,000Source | -1,373,000Source | -1,412,000Source | -1,203,000Source | -1,369,000Source | -1,396,000Source | -1,403,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 486,000Source | 384,000Source | 1,002,000Source | 793,000Source | 414,000Source | 1,234,000Source | 902,000Source | 991,000Source | 1,096,000Source | 1,197,000Source | 1,097,000Source | 3,833,000Source |
| Deferred Revenue, CurrentUSD | 3,766,000Source | 8,250,000Source | 1,678,000Source | 5,257,000Source | 9,142,000Source | 1,716,000Source | 6,931,000Source | 10,106,000Source | 3,333,000Source | 7,388,000Source | 10,808,000Source | 9,421,000Source |
| Deferred Revenue, NoncurrentUSD | 12,462,000Source | 16,050,000Source | 12,339,000Source | 12,751,000Source | 18,543,000Source | 12,999,000Source | 13,611,000Source | 18,177,000Source | 12,377,000Source | 14,433,000Source | 18,693,000Source | 27,725,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | 273,000Source | 273,000Source | 2,076,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -29,752,000Source | -3,001,000Source | 1,544,000Source | -30,364,000Source | -4,789,000Source | -4,143,000Source | -63,367,000Source | -18,582,000Source | -21,479,000Source | -26,353,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 178,000Source | 141,000Source | 187,000Source | 171,000Source | 188,000Source | 164,000Source | 699,000Source | 587,000Source | 562,000Source | 582,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,172,000Source | 1,217,000Source | 4,752,000Source | 5,077,000Source | 4,640,000Source | 4,287,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -154,000Source | -424,000Source | 316,000Source | -106,000Source | 446,000Source | -50,314,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | 0Source | 0Source | 0Source | 0Source | -5,280,000Source | 0Source | -1,803,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -8,078,000Source | -4,886,000Source | -18,919,000Source | -23,092,000Source | -28,566,000Source | 1,059,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -2,326,000Source | 1,903,000Source | -13,457,000Source | -2,308,000Source | 46,449,000Source | -46,159,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 55,000Source | 97,000Source | 522,000Source | 565,000Source | 674,000Source | 413,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 40,000Source | 15,000Source | 16,000Source | 23,000Source | 37,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 5,561,000Source | 5,044,000Source | 26,950,000Source | 35,857,000Source | 6,423,000Source | 1,632,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -4,848,000Source | 1,988,000Source | -5,030,000Source | 10,362,000Source | 24,056,000Source | -44,341,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 40,977,000Source | 28,306,000Source | 37,917,000Source | 42,775,000Source | 36,476,000Source | 48,342,000Source | 41,324,000Source | 46,354,000Source | 35,992,000Source | — |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 1,000Source | 14,000Source | 29,000Source | 9,000Source | 10,000Source | 13,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -5,000Source | -73,000Source | 396,000Source | -95,000Source | -250,000Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,199,000Source | 1,330,000Source | 1,601,000Source | 1,238,000Source | 1,172,000Source | 1,217,000Source | 4,752,000Source | 5,077,000Source | 4,640,000Source | — |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | — | — | 22,000Source | — |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | 0Source | 0Source | 22,000Source | 130,000Source | 145,000Source |
| Debt and Equity Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | — | -2,194,000Source |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | 6,000Source | -6,000Source | 0Source | -2,000Source | 24,000Source | -5,000Source | -8,000Source | -8,000Source | -176,000Source | — |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | -4,000Source | -23,000Source | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | 6,000Source | -6,000Source | 0Source | -2,000Source | 24,000Source | -5,000Source | -8,000Source | -4,000Source | -153,000Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 219,000Source | 448,000Source | 664,000Source | 1,678,000Source | 50,000Source | -231,000Source | 2,148,000Source | -269,000Source | -602,000Source | — |
| Gain (Loss) on Disposition of Assets for Financial Service OperationsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 11,000Source |
| General and Administrative ExpenseUSD | — | — | 4,191,000Source | 4,410,000Source | 5,218,000Source | 4,560,000Source | 5,084,000Source | 4,857,000Source | 18,460,000Source | 18,171,000Source | 17,302,000Source | 22,508,000Source |
| GoodwillUSD | — | — | 10,672,000Source | 10,672,000Source | 10,672,000Source | 10,672,000Source | 10,672,000Source | 10,672,000Source | 10,672,000Source | 10,672,000Source | 10,672,000Source | 10,672,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | 0Source | 0Source | 0Source | 14,840,000Source | — | — | 14,840,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source | — | — | — | — | -5,280,000Source | 0Source | -1,803,000Source | 541,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | — | -150,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -29,781,000Source | -3,034,000Source | 1,482,000Source | -30,464,000Source | -4,812,000Source | -4,139,000Source | -63,533,000Source | -18,609,000Source | -21,486,000Source | -26,273,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 29,000Source | 33,000Source | 62,000Source | 100,000Source | 23,000Source | -4,000Source | 166,000Source | 27,000Source | 7,000Source | -80,000Source |
| Nonoperating Income (Expense)USD | — | — | -25,966,000Source | 839,000Source | 10,467,000Source | -10,584,000Source | 2,804,000Source | 2,362,000Source | -32,028,000Source | 2,896,000Source | 1,451,000Source | -3,292,000Source |
| Operating ExpensesUSD | — | — | — | — | — | — | — | — | — | — | 33,007,000Source | 36,495,000Source |
| Operating Lease, ExpenseUSD | — | — | 300,000Source | 300,000Source | 300,000Source | 300,000Source | 300,000Source | 300,000Source | 1,200,000Source | 1,100,000Source | — | — |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | 0Source | -18,000Source | 26,000Source | 1,000Source | -185,000Source | -132,000Source | -670,000Source | -4,000Source | -2,152,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 6,625,000Source | 148,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 227,000Source | 0Source | 1,250,000Source | 229,000Source | 88,000Source | 648,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 3,544,000Source | 3,386,000Source | 943,000Source | 2,532,000Source | 1,575,000Source | 1,270,000Source | 13,609,000Source | 8,149,000Source | 7,588,000Source | 13,367,000Source |
| Gain (Loss) on Disposition of Assets | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 3,681,000Source | 3,779,000Source | 1,069,000Source | 2,765,000Source | 1,725,000Source | 1,502,000Source | 14,556,000Source | 9,499,000Source | 8,945,000Source | 14,703,000Source |
| Cost of Goods and Services Sold | — | — | — | —Source | — | — | — | —Source | — | —Source | —Source | —Source |
| Operating Income (Loss)USD | — | — | -3,786,000Source | -3,840,000Source | -8,923,000Source | -19,780,000Source | -7,593,000Source | -6,505,000Source | -36,619,000Source | -21,478,000Source | -24,733,000Source | -22,520,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | 0Source | -18,000Source | 26,000Source | 1,000Source | -185,000Source | -132,000Source | -670,000Source | -4,000Source | -2,152,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | -3,001,000Source | — | — | — | — | -68,647,000Source | -18,582,000Source | -23,282,000Source | -25,812,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source | — | — | — | — | -5,280,000Source | 0Source | -1,803,000Source | 541,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 29,000Source | 33,000Source | 62,000Source | 100,000Source | 23,000Source | -4,000Source | 166,000Source | 27,000Source | 7,000Source | -80,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -29,781,000Source | -3,034,000Source | 1,482,000Source | -30,464,000Source | -4,812,000Source | -4,139,000Source | -63,533,000Source | -18,609,000Source | -21,486,000Source | -26,273,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.13Source | -0.02Source | 0.01Source | -0.13Source | -0.02Source | -0.02Source | -0.28Source | -0.09Source | -0.12Source | -0.15Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.13Source | -0.02Source | -0.03Source | -0.13Source | -0.03Source | -0.02Source | -0.28Source | -0.09Source | -0.12Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 228,853,000Source | 188,835,000Source | 249,499,000Source | 228,356,000Source | 245,029,000Source | 226,054,000Source | 230,116,000Source | 200,193,000Source | 172,663,000Source | 169,792,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 228,853,000Source | 188,835,000Source | 261,471,000Source | 228,356,000Source | 261,175,000Source | 226,054,000Source | 230,116,000Source | 200,193,000Source | 172,663,000Source | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | 0Source | 0Source | 22,000Source | 130,000Source | 145,000Source |
| Costs and ExpensesUSD | — | — | 7,467,000Source | 7,619,000Source | 9,992,000Source | 22,545,000Source | 9,318,000Source | 8,007,000Source | 51,175,000Source | 30,977,000Source | — | — |
| Debt and Equity Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | — | -2,194,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 178,000Source | 141,000Source | 187,000Source | 171,000Source | 188,000Source | 164,000Source | 699,000Source | 587,000Source | 562,000Source | 582,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | -4,000Source | -23,000Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 219,000Source | 448,000Source | 664,000Source | 1,678,000Source | 50,000Source | -231,000Source | 2,148,000Source | -269,000Source | -602,000Source | — |
| General and Administrative ExpenseUSD | — | — | 4,191,000Source | 4,410,000Source | 5,218,000Source | 4,560,000Source | 5,084,000Source | 4,857,000Source | 18,460,000Source | 18,171,000Source | 17,302,000Source | 22,508,000Source |
| Gross ProfitUSD | — | — | — | — | — | — | — | — | — | — | 8,274,000Source | 13,975,000Source |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | — | 829,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 366,000Source | 397,000Source | 378,000Source | 454,000Source | 405,000Source | 478,000Source | 1,691,000Source | 1,715,000Source | 1,629,000Source | — |
| Nonoperating Income (Expense)USD | — | — | -25,966,000Source | 839,000Source | 10,467,000Source | -10,584,000Source | 2,804,000Source | 2,362,000Source | -32,028,000Source | 2,896,000Source | 1,451,000Source | -3,292,000Source |
| Operating ExpensesUSD | — | — | — | — | — | — | — | — | — | — | 33,007,000Source | 36,495,000Source |
| Operating Lease, ExpenseUSD | — | — | 300,000Source | 300,000Source | 300,000Source | 300,000Source | 300,000Source | 300,000Source | 1,200,000Source | 1,100,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 3,271,000Source | 3,171,000Source | 4,774,000Source | 3,106,000Source | 4,234,000Source | 3,114,000Source | 17,729,000Source | 12,472,000Source | 15,705,000Source | 13,987,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 3,544,000Source | 3,386,000Source | 943,000Source | 2,532,000Source | 1,575,000Source | 1,270,000Source | 13,609,000Source | 8,149,000Source | 7,588,000Source | 13,367,000Source |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
Offerings
Registration 333-294202
Filing attachments
lctx-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 lctx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 • Announced Progress with Wholly-Owned Corneal Endothelial Disease Cell Therapy Program (COR1) • Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD As Founding Member • Cash, cas…
Read attachment ↗lctx-ex99_1.htm · 8-K · 2026-05-12
EX-99.1 2 lctx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 LINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 • Launched New Corneal Endothelial Disease Cell Therapy Program • Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative • Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study • Established…
Read attachment ↗lctx-ex4_3.htm · S-3 · 2026-03-11
Exhibit 4.3 LINEAGE CELL THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20__ Debt Securities Table Of Contents Page article 1 DEFINITIONS …
Read attachment ↗lctx-ex99_1.htm · 8-K · 2026-03-05
EX-99.1 2 lctx-ex99_1.htm EX-99.1 EX-99.1 LINEAGE CELL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • Positive RG6501 (OpRegen® Cell Therapy) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 • Achieved First Milestone Under Worldwide Collaboration with Genentech Based on RG6501 (OpRegen Cell Therapy) Program Manufacturing and Clinical Advancements • Successfully Demonstrated the High-Scale P…
Read attachment ↗lctx-ex99_1.htm · 8-K · 2025-11-06
EX-99.1 2 lctx-ex99_1.htm EX-99.1 EX-99.1 LINEAGE CELL THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ● Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 ● Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for Sensorineural Hearing Loss ● Initiated Manufacturing Scale Project in Type 1 Diabetes Cell Therapy CARLSBAD, CA - November 6, 2025 - Lineage Cell …
Read attachment ↗lctx-ex99_1.htm · 8-K · 2025-08-12
EX-99.1 2 lctx-ex99_1.htm EX-99.1 EX-99.1 LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 • Successfully Reduced-to-Practice Critical Aspect of Commercial-Scale, Cell-Based, GMP Production Processes • First Chronic Patient Treated in New Clinical Study of OPC1 in Patients with Subacute and Chronic Spinal Cord Injury •…
Read attachment ↗